BCL2 and breast cancer: Catechin derivatives were investigated for their role in TNBC tumorigenesis using in vitro and in silico approaches, revealing interactions with critical hub genes (CASP3, MAPK14, PPARG, MMP3, SERPINE1, SRC, BCL2, EGFR, MMP9, and KDR) that contribute to BC mitigation through DNA damage repair from UV-A exposure and lipid peroxidation-induced apoptosis, while also exhibiting strong binding affinity to extracellular domains of EGFR, comparable to the control drug erlotinib [31].